This report will examine how TMS became a frequently used treatment for depression in the United States despite what the research of the last decade shows about its very questionable effectiveness.
Read More »Author: NCHR Author
NCHR Comments on the FDA’s Post-Marketing Pediatric-Focused Product Safety Reviews
September 28 2018. In its public comment, NCHR calls for better monitoring of children’s drug side effects, stronger warning labels, and parent-friendly information about risks of ADHD drugs and medical devices. The FDA’s current reporting system misses many adverse reactions due to under-reporting, and psychiatric risks from ADHD medications need more prominent warnings.
Read More »NCHR Testimony at the FDA’s Pediatric Advisory Committee Meeting
September 20 2018. At an FDA Advisory Committee meeting, NCHR challenges FDA’s safety conclusions about psychiatric drugs for children, arguing Lexapro lacks evidence for kids under 12 and Intuniv causes serious side effects. Despite NCHR’s concerns, the Pediatric Advisory Committee voted 11-1 to continue current monitoring rather than requiring stronger warnings or additional research.
Read More »NCHR Testimony on Prucalopride for Chronic Idiopathic Constipation
NCHR testifies against approving prucalopride at the FDA. Data shows that studies showing the efficacy and safety of this drug are from 1999 and have less than 10% of racial minorities in their clinical trials.
Read More »NCHR Testimony on the Opioid Sufentanil
NCHR testifies against the approval of Sufentanil, a new sublingual opioid 10-15 times more potent than fentanyl.
Read More »